Tempest Therapeutics Statistics
Share Statistics
Tempest Therapeutics has 3.66M
shares outstanding. The number of shares has increased by -4.76%
in one year.
| Shares Outstanding | 3.66M |
| Shares Change (YoY) | -4.76% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 26.28% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 6,666 |
| FTD / Avg. Volume | 10.87% |
Short Selling Information
The latest short interest is 109.25K, so 3.1% of the outstanding
shares have been sold short.
| Short Interest | 109.25K |
| Short % of Shares Out | 3.1% |
| Short % of Float | 3.37% |
| Short Ratio (days to cover) | 1.91 |
Valuation Ratios
The PE ratio is -7.23 and the forward
PE ratio is -4.17.
Tempest Therapeutics's PEG ratio is
0.34.
| PE Ratio | -7.23 |
| Forward PE | -4.17 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 15.83 |
| P/FCF Ratio | -9.05 |
| PEG Ratio | 0.34 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Tempest Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21,
with a Debt / Equity ratio of 0.8.
| Current Ratio | 2.21 |
| Quick Ratio | 2.21 |
| Debt / Equity | 0.8 |
| Debt / EBITDA | -0.38 |
| Debt / FCF | -0.46 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,743,458.33 |
| Employee Count | 24 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 100.29% in the
last 52 weeks. The beta is -2.21, so Tempest Therapeutics's
price volatility has been lower than the market average.
| Beta | -2.21 |
| 52-Week Price Change | 100.29% |
| 50-Day Moving Average | 8.62 |
| 200-Day Moving Average | 12.79 |
| Relative Strength Index (RSI) | 41.77 |
| Average Volume (20 Days) | 61,334 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.03M |
| Net Income | -41.84M |
| EBITDA | -40.14M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.5 |
Full Income StatementBalance Sheet
The company has 30.27M in cash and 15.37M in
debt, giving a net cash position of 14.9M.
| Cash & Cash Equivalents | 30.27M |
| Total Debt | 15.37M |
| Net Cash | 14.9M |
| Retained Earnings | -207.11M |
| Total Assets | 41.49M |
| Working Capital | 17.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -33.03M
and capital expenditures -435K, giving a free cash flow of -33.46M.
| Operating Cash Flow | -33.03M |
| Capital Expenditures | -435K |
| Free Cash Flow | -33.46M |
| FCF Per Share | -1.2 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
